IL-21 蛋白, Human

IL-21 Protein, Human is a class 1 cytokine, which is produced by activated CD4⁺ T cells. IL-21 Protein stimulation of T cells, B cells and NK cells leads to enhanced proliferation and mature effector function.

白细胞介素-21 (IL-21) 是一种多效细胞因子，在先天免疫和适应性免疫以及自身免疫调节中具有关键功能。IL-21 具有一系列可能增强抗肿瘤免疫反应的活性。IL-21 作为单一药物治疗黑色素瘤。IL-21 与单克隆抗体或信号抑制剂联合使用，还具有显着的抗多种癌症活性^[1]。重组人白细胞介素 21 (rIL-21) 是一种人重组白细胞介素，与单克隆抗体西妥昔单抗结合，靶向表皮生长因子受体^[2]。

1.The ED₅₀ is <0.5 ng/mL as measured by Mino cells, corresponding to a specific activity of >2.0 × 10⁶ units/mg.
2.Measured by its binding ability in a functional ELISA. Immobilized Human IL-21R at 5 μg/mL (100 μL/well) can bind Human IL-21. The ED₅₀ for this effect is 5.056 ng/mL.
3.Measured by its ability to enhance IFN-gamma secretion in NK-92 human natural killer lymphoma cells. The ED₅₀ for this effect is 6.707 ng/mL.

• 
  Measured by its ability to enhance IFN-gamma secretion in NK-92 human natural killer lymphoma cells. The ED₅₀ for this effect is 6.707 ng/mL, corresponding to a specific activity is 1.491×10⁵ U/mg.

Human

E. coli

Tag Free

Q9HBE4-1 (Q32-S162)

59067  [NCBI]

QDRHMIRMRQLIDIVDQLKNYVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSCDSYEKKPPKEFLERFKSLLQKMIHQHLSSRTHGSEDS

Approximately 15.4-18 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized after extensive dialysis against PBS or 20 mM PB, 150 mM NaCl, pH 7.4 or PBS, pH 7.4, 5 % trehalose, 5 % mannitol and 0.01% Tween80.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Davis ID, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res. 2009 Mar 15;15(6):2123-9.  [Content Brief]

  [2]. Steele N, et al. A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. Br J Cancer. 2012 Feb 28;106(5):793-8.  [Content Brief]